



June 1, 2021

Verity Pharmaceuticals Inc. (“Verity”) provides this notice to all 340B covered entities regarding the implementation of a Supply Allocation Plan for the TRELSTAR® (triptorelin pamoate for injectable suspension) 6-month dosing regimen as noted below:

Product	Description	NDC NUMBERS
TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension)	1 KIT in 1 CARTON * 2 mL in 1 VIAL, SINGLE-DOSE * 2 mL in 1 SYRINGE	0023-5906-23 74676-5906-01

TRELSTAR is the only gonadotropin-releasing hormone (GnRH) agonist approved for use in the United States for patients with prostate cancer that differs from natural GnRH by a single amino acid. Trelstar® has been engineered to deliver superagonist activity.

As Verity expects that the statutory 340B ceiling price of the NDCs noted above will drop to a penny, Verity anticipates challenges with equitable market distribution of the drug. As such, Verity will implement a Supply Allocation Program to minimize disruptions to patient care and prevent an imbalance between supply and demand. The Supply Allocation program for TRELSTAR, as described in our January 2021 notice, will continue to be in place through December 31, 2021. Under this program, Verity will only allow direct wholesaler and indirect customer purchases that comply with the purchase volumes as determined by Verity for the aforementioned specified time period.

Verity has established specified purchasing limits based on available supply and prior purchasing history. Purchasing limits will be applied equally to all direct and indirect customers. For wholesalers and direct purchasers, purchase limits have been established for each customer based on the average sales transactions between the customer and Verity directly. For indirect customers (including purchases by Covered Entities under the 340B program), the purchase limits have been established based on the customers’ historical purchases. The same allocation procedure will apply to both 340B covered entities and non-340B customers and Verity will continue to make Trelstar available to covered entities at a price no higher than the statutorily calculated ceiling price.

Verity remains committed to its obligations under the 340B program and will make every effort to ensure that TRELSTAR is available to 340B covered entities in a manner that is no more restrictive than it is for non-340B customers, and is consistent with past purchase volumes..

If you have any questions regarding this program, please call 1-866-755-3315 from 8AM to 8PM ET, Monday through Friday (except holidays).